Walleye Capital’s BioXcel Therapeutics BTAI Stock Holding History

Walleye Capital’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,306	Closed	-$487K	–	3232
2022 Q2	$487K	Buy	+2,306	New	+$485K	0.01%	1047

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's BTAI Position: Q3 2022 in Review

Walleye Capital sold out of BioXcel Therapeutics (BTAI) in Q3 2022, closing a stake of 2,306 shares — an estimated $487K sold.

Walleye Capital first reported a position in BTAI in Q2 2022 and held it in 1 quarter. The position peaked at $487K in Q2 2022. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2022.

Walleye Capital reported no remaining BioXcel Therapeutics position as of Q3 2022 after selling out during the quarter.
Walleye Capital sold 2,306 BioXcel Therapeutics shares in Q3 2022, an estimated $487K.
Walleye Capital first reported a position in BioXcel Therapeutics in Q2 2022 and held it in 1 quarter.
Walleye Capital's BioXcel Therapeutics position peaked at $487K in Q2 2022.
85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2022.

Based on Walleye Capital's 13F filing for Q3 2022, filed 14 Nov 2022.